201 related articles for article (PubMed ID: 26312576)
21. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
[TBL] [Abstract][Full Text] [Related]
22. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Boonen S; Klemes AB; Zhou X; Lindsay R
J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
[TBL] [Abstract][Full Text] [Related]
24. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study.
Schmidt J; Dahlgren E; Brännström M; Landin-Wilhelmsen K
Clin Endocrinol (Oxf); 2012 Aug; 77(2):207-14. PubMed ID: 22385110
[TBL] [Abstract][Full Text] [Related]
25. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
Marcus R; Wong M; Heath H; Stock JL
Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
[TBL] [Abstract][Full Text] [Related]
26. [Quality of life in the treatment assessment of postmenopausal osteoporosis].
Hu YF; Sun ZQ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 30(3):299-303. PubMed ID: 16045018
[TBL] [Abstract][Full Text] [Related]
27. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures].
Kuzma M; Payer J
Cas Lek Cesk; 2010; 149(5):211-6. PubMed ID: 20629339
[TBL] [Abstract][Full Text] [Related]
28. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.
Haguenauer D; Welch V; Shea B; Tugwell P; Adachi JD; Wells G
Osteoporos Int; 2000; 11(9):727-38. PubMed ID: 11148800
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
30. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
31. Calcium plus vitamin D supplementation and the risk of fractures.
Jackson RD; LaCroix AZ; Gass M; Wallace RB; Robbins J; Lewis CE; Bassford T; Beresford SA; Black HR; Blanchette P; Bonds DE; Brunner RL; Brzyski RG; Caan B; Cauley JA; Chlebowski RT; Cummings SR; Granek I; Hays J; Heiss G; Hendrix SL; Howard BV; Hsia J; Hubbell FA; Johnson KC; Judd H; Kotchen JM; Kuller LH; Langer RD; Lasser NL; Limacher MC; Ludlam S; Manson JE; Margolis KL; McGowan J; Ockene JK; O'Sullivan MJ; Phillips L; Prentice RL; Sarto GE; Stefanick ML; Van Horn L; Wactawski-Wende J; Whitlock E; Anderson GL; Assaf AR; Barad D;
N Engl J Med; 2006 Feb; 354(7):669-83. PubMed ID: 16481635
[TBL] [Abstract][Full Text] [Related]
32. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
[TBL] [Abstract][Full Text] [Related]
33. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
[TBL] [Abstract][Full Text] [Related]
34. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
35. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
36. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
38. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
39. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W
Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256
[TBL] [Abstract][Full Text] [Related]
40. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
